SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours

被引：2
|
作者：
Baselga, J. [1 ]
Cortes Castan, J. [2 ,3 ]
De Laurentiis, M. [4 ]
Dieras, V. [5 ]
Harbeck, N. [6 ]
Hsu, J. [7 ]
Jin, H. [8 ]
Schimmoller, F.
Wilson, T. R. [9 ]
Im, Y-H. [10 ]
Jacot, W. [11 ]
Krop, I. E. [12 ]
Verma, S. [13 ]
机构：
[1] Mem Hosp, Mem Sloan Kettering Canc Ctr, Dept Med, Human Oncol & Pathogenesis Program HOPP, New York, NY USA
[2] Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain
[3] Ramon & Cajal Univ Hosp, Madrid, Spain
[4] Fdn G Pascale, Ist Nazl Tumori, Breast Oncol Dept, Naples, Italy
[5] Inst Curie, Dept Med Oncol, Paris, France
[6] Univ Munich, Breast Canc Ctr, Munich, Germany
[7] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[8] Genentech Inc, Dept Oncol, San Francisco, CA 94080 USA
[9] Genentech Inc, Oncol Biomarker Dept, San Francisco, CA 94080 USA
[10] Samsung Med Ctr, Dept Med, Seoul, South Korea
[11] Inst Canc Montpellier ICM, Dept Med Oncol, Montpellier, France
[12] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[13] Univ Calgary, Dept Oncol, Tom Baker Canc Ctr, Calgary, AB, Canada
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw365.92
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
313TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [1] SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors
    Baselga, Jose
    Cortes, Javier
    DeLaurentils, Michelino
    Dent, Susan
    Dieras, Veronique
    Harbeck, Nadia
    Hsu, Jerry Y.
    Jin, Huan
    Schimmoller, Frauke
    Wilson, Timothy R.
    Im, Young-Hyuck
    Jacot, William
    Krop, Ian E.
    Verma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors.
    Baselga, Jose
    Cortes, Javier
    De Laurentiis, Michele
    Dieras, Veronique
    Harbeck, Nadia
    Hsu, Jerry Y.
    Ng, Vivian
    Schimmoller, Frauke
    Wilson, Timothy R.
    Im, Young-Hyuck
    Jacot, William
    Krop, Ian E.
    Verma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA mutant tumors.
    Baselga, Jose
    Cortes, Javier
    De Laurentiis, Michelino
    Dieras, Veronique
    Harbeck, Nadia
    Im, Young-Hyuck
    Jacot, William
    Krop, Ian E.
    Verma, Sunil
    Wilson, Timothy R.
    Lin, Ray
    Schimmoller, Frauke
    Hsu, Jerry Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors
    Baselga, J.
    Cortes, J.
    De Laurentiis, M.
    Dieras, V.
    Harbeck, N.
    Hsu, J.
    Jin, H.
    Schimmoller, F.
    Wilson, T. R.
    Im, Y-H
    Jacot, W.
    Krop, I. E.
    Verma, S.
    CANCER RESEARCH, 2016, 76
  • [5] SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors
    Baselga, J.
    Cortes, J.
    De laurentiis, M.
    Dent, S.
    Dieras, V.
    Harbeck, N.
    Hsu, J.
    Jin, H.
    Schimmoller, F.
    Wilson, T. R.
    Im, Y-H
    Jacot, W.
    Krop, I. E.
    Verma, S.
    CANCER RESEARCH, 2017, 77
  • [6] A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor positive (HR plus ) advanced breast cancer (BC).
    Dickler, Maura N.
    Saura, Cristina
    Richards, Donald A.
    Krop, Ian E.
    Cervantes, Andres
    Bedard, Philippe L.
    Patel, Manish R.
    Pusztai, Lajos
    Oliveira, Mafalda
    Ware, Joseph A.
    Jin, Huan
    Wilson, Timothy R.
    Stout, Thomas
    Wei, Michael C.
    Hsu, Jerry Y.
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.
    Baselga, Jose
    Dent, Susan Faye
    Cortes, Javier
    Im, Young-Hyuck
    Dieras, Veronique
    Harbeck, Nadia
    Krop, Ian E.
    Verma, Sunil
    Wilson, Timothy R.
    Jin, Huan
    Wang, Lijia
    Schimmoller, Frauke
    Hsu, Jerry Y.
    He, Jing
    DeLaurentiis, Michelino
    Drullinsky, Pamela
    Jacot, William
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)
  • [8] A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors
    Jhaveri, Komal
    Juric, Dejan
    Saura, Cristina
    Cervantes, Andres
    Melnyk, Anton
    Patel, Manish R.
    Oliveira, Mafalda
    Gambardella, Valentina
    Ribrag, Vincent
    Ma, Cynthia X.
    Aljumaily, Raid
    Bedard, Philippe L.
    Sachdev, Jasgit C.
    Bond, John
    Jones, Surai
    Wilson, Timothy R.
    Wei, Michael C.
    Baselga, Jose
    CANCER RESEARCH, 2018, 78 (13)
  • [9] Phase I evaluation of the PI3 kinase (PI3K) inhibitor taselisib (GDC-0032) in multiple locally advanced or metastatic PIK3CA mutant solid tumor types.
    Jhaveri, Komal L.
    Bedard, Philippe L.
    Cejalvo, Juan Miguel
    Hart, Lowell L.
    Juric, Dejan
    Kelly, Karen
    Lockhart, A. Craig
    Melnyk, Anton
    Moore, Kathleen N.
    Nemunaitis, John J.
    Oliveira, Mafalda
    Patel, Manish R.
    Sachdev, Jasgit
    Smith, David
    VanderWalde, Ari
    Ware, Joseph A.
    Jin, Huan
    Wilson, Timothy R.
    Wei, Michael C.
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
    Dent, S.
    Cortes, J.
    Im, Y-H
    Dieras, V
    Harbeck, N.
    Krop, I. E.
    Wilson, T. R.
    Cui, N.
    Schimmoller, F.
    Hsu, J. Y.
    He, J.
    De Laurentiis, M.
    Sousa, S.
    Drullinsky, P.
    Jacot, W.
    ANNALS OF ONCOLOGY, 2021, 32 (02) : 197 - 207
12345